Browsing by Author "de Bruin-Weller M."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    ItemMetadata only
    A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative
    (2023-09-01) Zuberbier T.; Abdul Latiff A.; Aggelidis X.; Augustin M.; Balan R.G.; Bangert C.; Beck L.; Bieber T.; Bernstein J.A.; Bertolin Colilla M.; Berardi A.; Bedbrook A.; Bindslev-Jensen C.; Bousquet J.; de Bruin-Weller M.; Bruscky D.; Buyuktiryaki B.; Canonica G.W.; Castro C.; Chanturidze N.; Chong-Neto H.J.; Chu C.Y.; Chularojanamontri L.; Cork M.; Criado R.F.J.; Barredo L.C.; Custovic A.; Darsow U.; Emurlai A.; de Pablo A.; Del Giacco S.; Girolomoni G.; Deleva Jovanova T.; Deleuran M.; Douladiris N.; Duarte B.; Dubakiene R.; Eller E.; Engel-Yeger B.; Ensina L.F.; Filho N.R.; Flohr C.; Fomina D.; Francuzik W.; Galimberti M.L.; Giménez-Arnau A.M.; Godse K.; Mortz C.G.; Gotua M.; Hide M.; Hoetzenecker W.; Hunzelmann N.; Irvine A.; Jack C.; Kanavarou I.; Katoh N.; Kinaciyan T.; Kocatürk E.; Kulthanan K.; Lapeere H.; Lau S.; Machado Forti Nastri M.; Makris M.; Mansour E.; Marsland A.; Morelo Rocha Felix M.; Moschione Castro A.P.; Nettis E.; Nicolas J.F.; Nosbaum A.; Odemyr M.; Papapostolou N.; Parisi C.A.S.; Paudel S.; Peter J.; Pokharel P.; Puig L.; Quint T.; Ramon G.D.; Regateiro F.; Ricci G.; Rosario C.; Sackesen C.; Schmid-Grendelmeier P.; Serra-Baldrich E.; Siemens K.; Smith C.; Staubach P.; Stevanovic K.; Su-Kücük Ö.; Sussman G.; Tavecchio S.; Teovska Mitrevska N.; Thaci D.; Toubi E.; Traidl-Hoffmann C.; Treudler R.; Vadasz Z.; van Hofman I.; Ventura M.T.; Mahidol University
    Introduction: The integrated care pathways for atopic dermatitis (AD-ICPs) aim to bridge the gap between existing AD treatment evidence-based guidelines and expert opinion based on daily practice by offering a structured multidisciplinary plan for patient management of AD. ICPs have the potential to enhance guideline recommendations by combining interventions and aspects from different guidelines, integrating quality assurance, and describing co-ordination of care. Most importantly, patients can enter the ICPs at any level depending on AD severity, resources available in their country, and economic factors such as differences in insurance reimbursement systems. Methods: The GA2LEN ADCARE network and partners as well as all stakeholders, abbreviated as the AD-ICPs working group, were involved in the discussion and preparation of the AD ICPs during a series of subgroup workshops and meetings in years 2020 and 2021, after which the document was circulated within all GAL2EN ADCARE centres. Results: The AD-ICPs outline the diagnostic procedures, possible co-morbidities, different available treatment options including differential approaches for the pediatric population, and the role of the pharmacists and other stakeholders, as well as remaining unmet needs in the management of AD. Conclusion: The AD-ICPs provide a multidisciplinary plan for improved diagnosis, treatment, and patient feedback in AD management, as well as addressing critical unmet needs, including improved access to care, training specialists, implementation of educational programs, assessment on the impact of climate change, and fostering a personalised treatment approach. By focusing on these key areas, the initiative aims to pave the way for a brighter future in the management of AD.
  • No Thumbnail Available
    ItemMetadata only
    International survey of treatment practices for atopic dermatitis in pregnant and breastfeeding women: Physician perspectives
    (2025-01-01) Pereira M.P.; Stevanovic K.; Kocatürk E.; Meesch C.; van Hofman I.; Vaswani P.S.; Bernstein J.A.; Bruscky D.; Chong-Neto H.J.; Chu C.Y.; Criado R.F.J.; Ensina L.F.; Giménez-Arnau A.M.; Godse K.; Gotua M.; Gregoriou S.; Kulthanan K.; Mortz C.G.; Mitrevska N.T.; Özkaya E.; Pudasaini P.; Felix M.M.R.; Pérez C.R.; Parisi C.A.S.; Ramón G.N.; Vakirlis E.; Zhao Z.; Beck L.A.; de Bruin-Weller M.; Cork M.; Katoh N.; Werfel T.; Worm M.; Wollenberg A.; Zuberbier T.; Pereira M.P.; Mahidol University
    Background and Objectives: Systemic treatment of pregnant/breastfeeding atopic dermatitis (AD) patients is challenging due to limited safety data. We explored treatment practices with systemic agents, including the guideline-recommended cyclosporine as the first systemic choice as well as emerging therapies, in this vulnerable population. Patients and Methods: The Global Allergy and Asthma Excellence Network (GA2LEN) ADCARE initiative collected data from physicians worldwide who treat pregnant women with AD. Physicians completed an electronic questionnaire on the use of systemic agents in pregnant/breastfeeding AD patients. Results: 103 physicians from 32 countries completed the survey, primarily dermatologists (n = 48) or allergologists (n = 43). Antihistamines were the systemic drug most often considered to be used during pregnancy/breastfeeding (n = 73/81, 90.1%), with fewer physicians considering the use of systemic agents for the first trimester compared to later stages of pregnancy. For acute flares, systemic corticosteroids (n = 34/80, 42.5%) were preferred, followed by biologics and antihistamines (each n = 15/80, 18.8%). Although the guideline-recommended cyclosporine is sometimes considered for AD during pregnancy (n = 38/81, 46.9%), it was rarely considered as the preferred drug by physicians (n = 1/80, 1.25%). Conclusions: Our study shows a misalignment between guideline recommendations and prescription patterns and highlights an unmet need for knowing and using the existing recommendations.